Literature DB >> 28173738

Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile.

J O Latino1, S Udry1,2, F M Aranda2, S D A Perés Wingeyer2, D S Fernández Romero1, G F de Larrañaga2.   

Abstract

Conventional treatment of obstetric antiphospholipid syndrome fails in approximately 20-30% of pregnant women without any clearly identified risk factor. It is important to identify risk factors that are associated with these treatment failures. This study aimed to assess the impact of risk factors on pregnancy outcomes in women with obstetric antiphospholipid syndrome treated with conventional treatment. We carefully retrospectively selected 106 pregnancies in women with obstetric antiphospholipid syndrome treated with heparin + aspirin. Pregnancy outcomes were evaluated according to the following associated risk factors: triple positivity profile, double positivity profile, single positivity profile, history of thrombosis, autoimmune disease, more than four pregnancy losses, and high titers of anticardiolipin antibodies and/or anti-βeta-2-glycoprotein-I (aβ2GPI) antibodies. To establish the association between pregnancy outcomes and risk factors, a single binary logistic regressions analysis was performed. Risk factors associated with pregnancy loss with conventional treatment were: the presence of triple positivity (OR = 5.0, CI = 1.4-16.9, p = 0.01), high titers of aβ2GPI (OR = 4.4, CI = 1.2-16.1, p = 0.023) and a history of more than four pregnancy losses (OR = 3.5, CI = 1.2-10.0, p = 0.018). The presence of triple positivity was an independent risk factor associated with gestational complications (OR = 4.1, CI = 1.2-13.9, p = 0.02). Our findings reinforce the idea that triple positivity is a categorical risk factor for poor response to conventional treatment.

Entities:  

Keywords:  Antiphospholipid syndrome; Hughes syndrome; anticardiolipin antibodies; pregnancy; thrombosis

Mesh:

Substances:

Year:  2017        PMID: 28173738     DOI: 10.1177/0961203317692432

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  10 in total

1.  A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.

Authors:  Sebastián Udry; José Omar Latino; Cristina Belizna; Silvia Perés Wingeyer; Diego Santiago Fernández Romero; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

Review 2.  Clinical features of new-onset systemic lupus erythematosus during pregnancy in Central China: a retrospective study of 68 pregnancies.

Authors:  Xiaodan He; Dongbin Jiang; Zhenbo Wang; Yao Li; Jingjing Wang; Dalin Xu; Jianqiang Chen; Xiaokang Liu; Guanmin Gao
Journal:  Clin Rheumatol       Date:  2020-10-16       Impact factor: 2.980

3.  What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?

Authors:  Jose Omar Latino; Sebastián Udry; Silvia Perés Wingeyer; Diego Fernández Romero; Paula Micone; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

4.  Treatment of Refractory/High-Risk Pregnancies With Antiphospholipid Syndrome: A Systematic Review of the Literature.

Authors:  Ariela Hoxha; Daniela Tormene; Elena Campello; Paolo Simioni
Journal:  Front Pharmacol       Date:  2022-05-19       Impact factor: 5.988

Review 5.  Obstetric Anti-phospholipid Syndrome: State of the Art.

Authors:  Maria Chiara Gerardi; Melissa Alexandre Fernandes; Angela Tincani; Laura Andreoli
Journal:  Curr Rheumatol Rep       Date:  2018-08-13       Impact factor: 4.592

Review 6.  Effects of anti-beta 2-glycoprotein 1 antibodies and its association with pregnancy-related morbidity in antiphospholipid syndrome.

Authors:  Juan J Fierro; Manuela Velásquez; Angela P Cadavid; Karina de Leeuw
Journal:  Am J Reprod Immunol       Date:  2021-12-04       Impact factor: 3.777

Review 7.  Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults.

Authors:  Maria G Tektonidou; Laura Andreoli; Marteen Limper; Angela Tincani; Michael M Ward
Journal:  RMD Open       Date:  2019-04-28

8.  Pregnancy outcomes in patients with primary antiphospholipid syndrome: A systematic review and meta-analysis.

Authors:  Liping Liu; Dan Sun
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

9.  Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies.

Authors:  Maria-Grazia Lazzaroni; Micaela Fredi; Laura Andreoli; Cecilia Beatrice Chighizola; Teresa Del Ross; Maria Gerosa; Anna Kuzenko; Maria-Gabriella Raimondo; Andrea Lojacono; Francesca Ramazzotto; Sonia Zatti; Laura Trespidi; Pier-Luigi Meroni; Vittorio Pengo; Amelia Ruffatti; Angela Tincani
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

10.  Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study.

Authors:  Sara Del Barrio-Longarela; Víctor M Martínez-Taboada; Pedro Blanco-Olavarri; Ana Merino; Leyre Riancho-Zarrabeitia; Alejandra Comins-Boo; Marcos López-Hoyos; José L Hernández
Journal:  Clin Rev Allergy Immunol       Date:  2021-12-15       Impact factor: 10.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.